曲尼司特与转移因子联合应用防治支气管哮喘52例疗效观察

A method combining Tranilist with transfer-factor in treating asthma——An observation of 52 cases

本文采用肥大细胞膜稳定剂曲尼司特与免疫增强剂人脾转移因子联合应用防治支气管哮喘52例,总有效率96.1％,与钙通道阻滞剂硝苯吡啶为对照,两组疗效差异显著(P<0.01)。并对治疗组观察了三种不同类型支气管哮喘的疗效比较,效果均较满意,且组间无显著差异(P>0.05)。

A method, combined tranilist, mast coll membrane--stabilising agent, with human splenic cell transfer factor, immu-noenhacer, was used in treating 52 cases of patients suffered from asthma. The total effective rate is 96.1%. By contrast with the group of nifedipine, calcium channel blocker, there is significant difference statistically (P<0.01). A good result has been observed with this method in treating three sorts of asthma, without singificant difference be tween three groups (P>0.05).